Fuda Cancer Hospital
Fuda Cancer Hospital
Қытай, Гуаңджоу
| Қытай | Түркия | Австрия | |
| Протонды-сәулелік терапия | бастап $36,500 | бастап $70,000 | бастап $80,000 |
| Ларингэктомия | бастап $19,200 | бастап $8,000 | бастап $25,000 |
| Көмей рағын алып тастау операциясы | бастап $18,500 | бастап $9,000 | бастап $30,000 |
| Көмей рагында химиялық терапия | бастап $12,000 | бастап $5,000 | бастап $12,000 |
| Көмей рагында сәулелік терапия | бастап $14,000 | бастап $3,250 | бастап $6,918 |
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
Chinese hospitals use narrow-band imaging (NBI) and high-definition laryngostroboscopy to detect early-stage larynx cancer. For staging, centers utilize 3T MRI, dual-energy CT, and PET/CT scans. These protocols follow Chinese Society of Clinical Oncology (CSCO) guidelines to ensure accurate tumor mapping.
Bookimed Expert Insight: Diagnostic precision in China is driven by high patient volumes at tertiary centers. Xiamen Humanity Hospital serves around 1,000,000 patients annually. This massive scale allows specialists like Dr. Liu Shi Xin to refine staging accuracy. Major centers often integrate advanced PET/CT and MRI for complex cases before determining if voice-preserving surgery is possible.
Patient Consensus: Patients note that flexible laryngoscopy via the nose is typically the first step. They emphasize that while scans are helpful, direct laryngoscopy under anesthesia is vital for mapping and biopsy.
Voice-box preservation is standard in China through advanced surgical techniques. Leading facilities utilize partial laryngectomies and transoral laser surgery to remove tumors while protecting speech. Highly specialized teams also perform laryngeal transplants and subtotal reconstructions. These methods prioritize maintaining natural breathing and swallowing functions.
Bookimed Expert Insight: Patient volume significantly impacts surgical precision in China. Xiamen Humanity Hospital serves around 1,000,000 patients annually. High-volume centers often possess greater expertise in complex head-and-neck reconstructions. JCI-accredited facilities like Fuda Cancer Hospital focus on minimally invasive alternatives to radical surgery. This high caseload helps surgeons refine organ-preserving techniques that smaller clinics may not master.
Patient Consensus: Patients emphasize that voice-box preservation is possible but often results in a weaker or hoarser voice. Many suggest seeking second opinions at major cancer centers to confirm if a partial removal is oncologically safe.
Proton beam therapy is available and clinically safe for laryngeal cancer in specialized Chinese oncology centers. This advanced radiation targets tumors with extreme precision using the Bragg Peak effect. It stops at a defined depth. This prevents radiation from exiting through healthy throat tissues or vocal cords.
Bookimed Expert Insight: Professional leadership is the most reliable quality signal in China. Xiamen Humanity Hospital is led by Dr. Liu Shi Xin. He is the Vice Chairman of the Particle Therapy Committee in China. This confirms the clinic operates at the highest national level for proton and particle treatments. This clinical integration often outweighs the mere presence of the technology itself.
Patient Consensus: Patients emphasize that voice preservation and nutrition are their top priorities. Many recommend asking how proton therapy specifically improves their anatomical plan compared to standard IMRT before starting.
Voice rehabilitation after total laryngectomy primarily involves three options: tracheoesophageal puncture (TEP), an electrolarynx, or esophageal speech. TEP with a voice prosthesis is the gold standard for natural sound. Success depends on anatomy, healing, and access to specialized speech-language pathologists.
Bookimed Expert Insight: While TEP offers the most natural speech, centers like Xiamen Humanity Hospital focus on integrated oncology. Large facilities serving 1,000,000 patients annually often have higher access to multi-disciplinary teams. Reviewing whether a center offers minimally invasive options like cryosurgery or NanoKnife is vital. These technologies at Fuda Cancer Hospital suggest a focus on tissue preservation which aids recovery.
Patient Consensus: Patients note that the electrolarynx is a vital backup during the frustrating early recovery. Many emphasize that mastering voice care, including cleaning the prosthesis and managing stoma mucus, is a daily reality.
Immunotherapy is approved and available for larynx cancer in China. The National Medical Products Administration (NMPA) has authorized several immune checkpoint inhibitors. These treatments target recurrent or metastatic head and neck squamous cell carcinoma. This classification includes squamous cell cancers of the larynx.
Bookimed Expert Insight: China has become a global leader in domestic PD-1 drug development. Clinics like Xiamen Humanity Hospital are even accredited for Phase I-IV drug trials. This means patients often access the latest immunotherapy protocols through clinical trials or early-access domestic medications. These domestic drugs frequently cost up to 85% less than international brands including nivolumab.
Patient Consensus: Patients note immunotherapy often enters the conversation quickly once surgery or radiation options are exhausted. They emphasize visiting major hubs like Guangzhou or Beijing to find oncologists experienced in these specific protocols.